Shareholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended							12 Months Ended
	Jul. 10, 2017	Aug. 31, 2018	Jun. 30, 2018	May 31, 2018	Oct. 31, 2017	Aug. 31, 2017	Jul. 31, 2017	Feb. 28, 2017	Dec. 31, 2018	Dec. 31, 2017	Jun. 30, 2017	Apr. 30, 2017	Feb. 17, 2017
Preferred shares, shares authorized									2,000,000	2,000,000
Preferred shares, shares issued
Preferred shares, shares outstanding
Common stock, shares authorized									250,000,000	250,000,000
Common stock, no par value
Common stock, issued									127,136,000	126,866,000
Common stock, outstanding									127,136,000	126,866,000
Number of common stock issued value										$ 45,068
Ownership percentage	99.80%								20.00%
Noncash expense/gain									$ 5,402	3,932
General and Administrative [Member]
Noncash expense/gain									4,617	3,000
Hadasit Bio-Holdings, Ltd [Member]
Common shares issued	1,220,207
Number of common stock issued value	$ 3,800
Warrants exercisable term							5 years
Teva Pharmaceutical Industries, Ltd [Member]
Common shares issued	927,673
Number of common stock issued value	$ 2,800
Cell Cure Neurosciences, Ltd. [Member]
Ownership percentage	62.50%
Cell Cure Warrants [Member]
Noncash expense/gain									$ 400
Cell Cure Warrants [Member] | Consultants [Member]
Warrants expiring period, description									expiring in October 2020 and January 2024
Cell Cure Warrants [Member] | General and Administrative [Member]
Noncash expense/gain										600
Cell Cure Warrants [Member] | Other Long-term Liabilities [Member]
Noncash expense/gain									$ 400	$ 800
LifeMap Sciences, Inc. [Member]
Ownership percentage											100.00%
Hadasit Bio-Holdings, Ltd [Member]
Ownership percentage, non-controlling owners	21.20%						21.20%
Warrants issued to purchase ordinary shares							24,566
Warrants exercise price per share							$ 40.5359
Teva Pharmaceutical Industries, Ltd [Member]
Ownership percentage, non-controlling owners	16.10%
Cell Cure Neurosciences, Ltd. [Member] | Hadasit Bio-Holdings, Ltd [Member]
Purchase price, per share				$ 40.5359
Cell Cure Neurosciences, Ltd. [Member] | Teva Pharmaceutical Industries, Ltd [Member]
Purchase price, per share				$ 40.5359
Contribution Agreement [Member]
Ownership percentage										85.40%
Proportional transfer of carrying value										$ 5,500
Maximum [Member]
Ownership percentage													50.00%
Maximum [Member] | Cell Cure Warrants [Member] | Consultants [Member]
Warrants issued to purchase ordinary shares									13,738
Warrants exercise price per share									$ 40.00
Maximum [Member] | LifeMap Sciences, Inc. [Member]
Ownership percentage											82.00%
Minimum [Member] | Cell Cure Warrants [Member] | Consultants [Member]
Warrants exercise price per share									$ 32.02
Minimum [Member] | LifeMap Sciences, Inc. [Member]
Ownership percentage											78.00%
Cantor Fitzgerald & Co [Member]
Fair value available for grant									$ 24,200
Percentage of commission payable									3.00%
Cantor Fitzgerald & Co [Member] | Maximum [Member]
Aggregate offering price												$ 25,000
Alfred D. Kingsley [Member]
Common shares issued						300,000
Purchase price, per share						$ 2.81
Acquisition of common shares						300,000
Number of shares acquired from subsidiary in terms of exchange						421,500
AgeX Therapeutics, Inc. [Member] | Asset Contribution and Separation Agreement [Member]
Common stock sold for asset contribution, shares						28,800,000
Ownership percentage		80.40%	80.60%							85.40%
Proportional transfer of carrying value									$ 3,800
AgeX Therapeutics, Inc. [Member] | Asset Contribution and Separation Agreement [Member] | Juvenescence [Member]
Ownership percentage, non-controlling owners		40.20%
AgeX Therapeutics, Inc. [Member] | Asset Contribution and Separation Agreement [Member] | Investors [Member]
Common stock sold for asset contribution, shares						4,950,000
Common stock sold for asset contribution						$ 10,000
AgeX Therapeutics, Inc. [Member] | Asset Contribution and Separation Agreement [Member] | Juvenescence [Member]
Common shares issued		14,400,000
Purchase price, per share			$ 2.50
Common stock sold for asset contribution, shares			2,000,000
Common stock sold for asset contribution			$ 5,000
AgeX Therapeutics, Inc. [Member] | Asset Contribution and Separation Agreement [Member] | Third Party [Member]
Common stock sold for asset contribution, shares		80,000
Common stock sold for asset contribution		$ 200
Cell Cure Neurosciences, Ltd. [Member]
Proportional transfer of carrying value									$ 1,900	$ 3,500
Charge to equity, value										$ 10,100
Number of stock options exercised to purchase ordinary shares					4,400
Cell Cure Neurosciences, Ltd. [Member] | Hadasit Bio-Holdings, Ltd [Member]
Common shares issued				937			1,220,207
Number of common stock issued value							$ 3,800
Cell Cure Neurosciences, Ltd. [Member] | Teva Pharmaceutical Industries, Ltd [Member]
Common shares issued				937
Cell Cure Neurosciences, Ltd. [Member] | Maximum [Member]
Ownership percentage				99.00%	99.80%
Cell Cure Neurosciences, Ltd. [Member] | Minimum [Member]
Ownership percentage				98.80%	98.80%
OrthoCyte Corporation [Member]
Number of stock options exercised to purchase ordinary shares										51,000
OrthoCyte Corporation [Member] | Maximum [Member]
Ownership percentage										100.00%
OrthoCyte Corporation [Member] | Minimum [Member]
Ownership percentage										99.80%
Common Stock [Member]
Restricted stock, shares issued net of shares for tax withholdings									270,000
Common shares issued					11,057,693		4,924,542	7,453,704		18,511,000
Purchase price, per share					$ 2.60			$ 2.70
Number of common stock issued value					$ 26,700		$ 15,200	$ 18,500		$ 45,068
Number of stock options exercised to purchase ordinary shares										9,000